- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03409575
Efficacy of Neuromuscular Electrical Stimulation in Geriatric Population
Efficacy of Two Different Method of Neuromuscular Electrical Stimulation on Quadriceps Strength, Fatigue and Physical Function in Geriatric Population
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ordu, Turkey, 52100
- Sevim ACARÖZ CANDAN
-
-
Altinordu
-
Ordu, Altinordu, Turkey, 52100
- Sevim ACARÖZ CANDAN
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria includes
- age 60 years or older
- be able to climb one floor of stairs independently
- not participate in an exercise program to increase strength or physiotherapy programme.
Exclusion Criteria:
- having a medical condition in which NMES training is contraindicated
- having a cognitive impairment
- having implanted cardiac pacemaker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: 5 minutes stimulation
The biphasic, symmetrical waveform will be used.
The 100 Hz current will be applied for 5 minutes.
|
Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes.
NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.).
Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions).
Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used.
The 100 Hz current will be applied for 5 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes.
5 minutes of NMES will be made in 4 sets.
Fifteen contractions will be received at each set.
The intensity of the current will be increased until the visible contraction is taken.
|
|
Other: 10 minutes stimulation
The biphasic, symmetrical waveform will be used.
The 100 Hz current will be applied for 10 minutes.
|
Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes.
NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.).
Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions).
Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used.
The 100 Hz current will be applied for 10 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes.
10 minutes of NMES will be made in 2 sets.
Thirty contractions will be received at each set.
The intensity of the current will be increased until the visible contraction is taken.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Timed up and go test
Time Frame: 2 minutes
|
This test will be used to measure the progress of balance, sit to stand, and walking. The participants stands up upon therapist's command walks 3 meters, turns around, walks back to the chair and sits down. The time stops when the patient is seated. Time will be recorded. |
2 minutes
|
|
30-Second Chair Stand Test
Time Frame: 30 second
|
The 30CST is a measurement that assesses functional lower extremity strength in older adults.
The participant is encouraged to complete as many full stands as possible within 30 seconds.
The participant is instructed to fully sit between each stand.The score is the total number of stands within 30 seconds (more than halfway up at the end of 30 seconds counts as a full stand).
Incorrectly executed stands are not counted.
|
30 second
|
|
6 minute walk test
Time Frame: 6 minute
|
The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance.
The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
The participant walk for 6 minutes on 30 meter long way.
The total distance will be recorded at the end of the test.
|
6 minute
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Grip Strength
Time Frame: 5 minutes
|
The patient wiil squeeze the dynamometer as the arm is adjacent to the body, the elbow is at 90 ° flexion, the forearm is in the neutral position and the wrist is at 0-30 ° extension.
After the test is repeated three times, the highest score will be recorded.
The test will only be done for the dominant hand.
|
5 minutes
|
|
Berg Balance Scale
Time Frame: 10 minutes
|
The balance will be evaluated observational during 14 different balance activities. A five-point scale, ranging from 0-4. "0" indicates the lowest level of function and "4" the highest level of function. It's minimum and maximum scores ranged between 0 and 56. Interpretation: 41-56 = low fall risk 21-40 = medium fall risk 0 -20 = high fall risk |
10 minutes
|
|
Strength of Quadriceps muscle
Time Frame: 5 minutes.
|
Lafayette manuel muscle tester will be used to determine the strength of the Quadriceps.
The strength will be evaluated bilaterally three times and then the maximum value will be recorded.
|
5 minutes.
|
|
Short Physical Performance Battery
Time Frame: 3 minutes
|
The battery is an objective assessment tool for evaluating lower extremity functioning in older persons.
The battery is scored between 0-12 scores according to the balance, chair stand test performance and gait speed of the participant.
|
3 minutes
|
|
Fatigue Severity Scale
Time Frame: 5 minutes
|
The 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders.
Each item is scored between1 and 7. A low value (e.g., 1) indicates strong disagreement with the statement, whereas a high value (e.g., 7) indicates strong agreement.
A total score of 36 or more suggests that you may be suffering from the fatigue.
|
5 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sevim A CANDAN, T.C. ORDU ÜNİVERSİTESİ
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AR-1665
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-Related Atrophy
-
IRCCS Ospedale San RaffaeleAnnexon, Inc.CompletedGeographic Atrophy | Age Related Macular Degeneration | AMD | Age Related Macular Degeneration (AMD) | Geographic Atrophy Secondary to Age-related Macular Degeneration | Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
-
McGill University Health Centre/Research Institute...RecruitingFrailty | Fall Injury | Old Age; Atrophy | Age-Related Atrophy | Age-Related SarcopeniaCanada
-
i-Lumen Scientific AUS PTY LTDi-Lumen Scientific, Inc.RecruitingAge-Related Macular Degeneration | Geographic Atrophy Secondary to Age-related Macular Degeneration | Intermediate AMD | Age-related Macular Degeneration (ARMD)United Kingdom, Australia, United States, New Zealand
-
Alkeus Pharmaceuticals, Inc.CompletedGeographic Atrophy | Age Related Macular Degeneration | AMD | Atrophy, GeographicUnited States
-
University of UtahApellis Pharmaceuticals, Inc.Not yet recruitingGeographic Atrophy From Age-related Macular DegenerationUnited States
-
Michelle Abou-JaoudeInflammasome TherapeuticsActive, not recruitingAge-Related Macular Degeneration | Geographic AtrophyUnited States
-
National Eye Institute (NEI)CompletedAge-Related Macular DegenerationUnited States
-
Regeneron PharmaceuticalsRecruitingAge-related Macular Degeneration (AMD) | Geographic Atrophy (GA)Austria, United States, France, Germany, Hungary, United Kingdom, Spain, Italy, Canada, Poland
-
Musculoskeletal Transplant FoundationCompletedAge-Related AtrophyUnited States
-
Complement TherapeuticsRecruitingGeographic Atrophy Secondary to Age-related Macular DegenerationUnited States
Clinical Trials on 5 minutes stimulation
-
Karin PalmbladKarolinska InstitutetUnknown
-
University of RegensburgCompleted
-
Florida State UniversityNational Institute on Drug Abuse (NIDA); National Center for Advancing Translational...CompletedHIV/AIDS | Infectious Disease | Substance Use | Older Adults | Behavioral InterventionUnited States
-
Chang Gung Memorial HospitalRecruiting
-
Shanghai Zhongshan HospitalNot yet recruitingPostoperative Delirium | Cardiac Surgery
-
Medical University of South CarolinaCompleted
-
Mersin UniversityCompleted
-
Bayero University Kano, NigeriaCompletedStroke | Hemiparesis;Poststroke/CVANigeria
-
Sahmyook UniversityCompletedPrimary Dysmenorrhea | DysmucorrheaKorea, Republic of